-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

Benzinga·07/21/2026 13:56:31
Listen to the news
Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $90 to $89.